-
Product Insights
Kuopion OA – Kuopio Student Accommodation Complex – Northern Savo
The Kuopion OA – Kuopio Student Accommodation Complex – Northern Savo project involves the construction of a student accommodation complex with two buildings of 7 and 12 stories comprising 265 apartments in Kuopio, North Savo, Finland. Equip yourself with the essential tools needed to make informed and profitable decisions with our Kuopion OA – Kuopio Student Accommodation Complex – Northern Savo report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within...
-
Product Insights
Mosi-oa-Tunya Solar PV Park
Mosi-oa-Tunya Solar PV Park is a solar PV project located in Lusaka, Zambia. The project is owned by Enel Green Power SpA; Industrial Development Corporation (Zambia) Ltd and was developed by Enel Green Power SpA. The project came online in 2019. Empower your strategies with our Mosi-oa-Tunya Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OA-235i in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OA-235i in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OA-235i in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: OA-235i is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluticasone Propionate in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluticasone Propionate in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluticasone Propionate in Osteoarthritis Pain Drug Details: Fluticasone propionate (EP-104) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fluticasone Propionate in Eosinophilic Esophagitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluticasone Propionate in Eosinophilic Esophagitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluticasone Propionate in Eosinophilic Esophagitis Drug Details: Fluticasone propionate (EP-104) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OA-3 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OA-3 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OA-3 in Atopic Dermatitis (Atopic Eczema) Drug Details: OA-3 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OA-235i in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OA-235i in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OA-235i in Non-Alcoholic Steatohepatitis (NASH) Drug Details: OA-235i is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Avibactam + Aztreonam) in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Avibactam + Aztreonam) in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam + Aztreonam) in Urinary Tract Infections Drug Details:...
-
Sector Analysis
Hip Reconstruction Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Hip Reconstruction Market Report Overview The hip reconstruction market size was valued at $7.90 billion in 2023. The market is forecast to grow at a CAGR of more than 3% during 2023 and 2033. Hip reconstruction or hip replacement is a procedure that involves the replacement of the damaged or diseased parts of the hip joint, especially in patients with osteoarthritis (OA) and rheumatoid arthritis (RA), as well as in cases of fractures. Hip Reconstruction Market Outlook, 2022-2033 ($ Billion)...